Weight loss drug maker sinks 25% after new safety data spooks investors
RSS SUMMARY · AGGREGATED FROM CNBC
While the experimental drug met its key targets, analysts are concerned over the commercial opportunity due to side effects.
While the experimental drug met its key targets, analysts are concerned over the commercial opportunity due to side effects.
While the experimental drug met its key targets, analysts are concerned over the commercial opportunity due to side effects.
Continue Reading
The full story continues on CNBC.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.
The Source
CNBC
US
Airline profits set to halve this year as fuel costs jump by $100 billion: IATA
CNBC·1h ago·3 min read
US
Fragile ceasefire in jeopardy as Iran reportedly fires missiles at Israel
CNBC·14h ago·3 min read
US
‘Bring ’em on’: Most profitable airline Delta wants United’s crown over the Pacific, too
CNBC·17h ago·3 min read
US
Trump storms out of interview after being challenged about election fraud claims, DOJ fund
CNBC·17h ago·3 min read
Related
On this beat
Health
Eli Lilly Shares Rise Premarket on Late-Stage Weight Loss Trial Success
TWSJ·2h ago·3 min read
Health
Life After A Spinal Injury: A Guide to Physical And Mental Recovery
AOHL·3h ago·3 min read
Health
Novo Nordisk Weight-Loss Pill Prescriptions Hit Three Million Since Launch
TWSJ·5h ago·3 min read
Health
Robert Coles, Pulitzer-Winning Child Psychiatrist, Is Dead at 97
TNYT·13h ago·3 min read